LYPD4

Across TCGA pan-cancer cohorts, LYPD4 RNA is linked to patient survival in 12 of 34 cancer types, making it the most broadly survival-associated LYPD4 data layer compared with 3 for mutation status.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher LYPD4 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated LYPD4 expression acts as an unfavorable survival marker, although some lineages such as HNSC and ESCA show a favorable association.

KIRC, KICH, and UCS are the cancer types where LYPD4 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Tertile	All	0.728	0.834	<.001	121	view →
KICH	DFS	Tertile	III,IV	0.047	0.900	<.001	91	view →
UCS	DFS	Tertile	IV	0.237	0.840	<.001	36	view →
HNSC	OS	Tertile	All	0.821	0.721	.007	33	view →
CHOL	DFS	Tertile	IV	0.082	0.753	.008	27	view →
TGCT	DFS	Tertile	II,III,IV	0.678	1.000	.033	18	view →
THCA	OS	Quartile	II,III,IV	0.939	0.992	.001	12	view →
BRCA	DFS	Median	III,IV	0.330	0.658	.013	7	view →
ESCA	DFS	Quartile	III,IV	0.613	0.269	.012	6	view →
LIHC	OS	Tertile	III,IV	0.170	0.412	.032	6	view →
KIRP	OS	Tertile	All	0.486	0.794	.007	3	view →
BLCA	OS	Median	All	0.511	0.256	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 12 lineages.

LYPD4–KIRC (OS)

Open the KIRC breakdown →